Analytical Data
-
基因名
PI4Ka
- Application
-
别名
PIK4CA; PI4K-ALPHA; pi4K230
-
种属
Human
-
表达系统
E. coli
-
标签
N- His & GST
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P42356
-
表达区间
Met1~Trp300
-
分子量
64kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Phosphoinositide 3-kinase (PI3K) is a crucial enzyme involved in various cellular processes, including cell growth, proliferation, and survival. Among its isoforms, PI3K class I-alpha (PI3Kα, or PI4Ka) plays a fundamental role in mediating signaling pathways activated by growth factors and hormones. Dysregulation of PI3Kα is often associated with various diseases, particularly cancer, making it a significant target for therapeutic intervention. Research on recombinant PI4Ka protein offers insights into its structure, function, and regulatory mechanisms. Understanding the biochemical properties of PI4Ka, including its lipid-binding specificity and catalytic activity, is essential for the development of selective inhibitors that could serve as potential anticancer agents. Furthermore, studying the protein's interaction with other cellular components can elucidate its role in oncogenic signaling networks, thus paving the way for novel therapeutic strategies. Given the increasing interest in targeted therapies, the investigation of recombinant PI4Ka not only provides essential data for drug development but also enhances our understanding of the PI3K signaling pathway's complexity and its implications in disease pathology.
